NXGL
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Trades at a low multiple of sales, but value is eroded by lack of profitability.
- Low P/S ratio
- P/B ratio near 1.0
- No Graham Number available due to lack of earnings
- Forward P/E is unreliable given historical misses
Growth metrics are negative across all primary timeframes.
- Single analyst target of $2.00
- Negative YoY revenue growth
- Negative Q/Q revenue growth
- EPS growth declining sharply
Long-term trend is aggressively bearish.
- 5-year price change of -78.5%
- 1-year price change of -73.0%
- 18 quarters of poor earnings performance
Fundamental health is in the 'Weak' category per deterministic scorecard.
- Debt/Equity is below sector average
- Piotroski F-Score 1/9
- Quick Ratio 0.34 indicates poor liquid asset coverage
Non-dividend paying growth/distress stock.
- No dividend paid
- No history of payouts
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for NXGL and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
NXGL
NEXGEL, Inc.
Primary
|
-78.5% | -49.8% | -73.0% | -70.1% | -8.6% | +18.5% |
|
BRTX
BioRestorative Therapies, Inc.
Peer
|
-99.5% | -93.0% | -85.2% | -84.5% | +8.1% | -7.9% |
|
MGRX
Mangoceuticals, Inc.
Peer
|
-99.3% | -97.5% | -78.4% | -84.5% | +2.4% | +2.4% |
|
QUCY
Mainz Biomed N.V.
Peer
|
-98.2% | -91.0% | -84.9% | -67.3% | -19.4% | +9.9% |
|
BIAF
bioAffinity Technologies, Inc.
Peer
|
-99.5% | -98.4% | -92.9% | -86.5% | +9.8% | -1.5% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
NXGL
NEXGEL, Inc.
|
BEARISH | $6.41M | - | -52.7% | -26.3% | $0.76 | |
|
BRTX
BioRestorative Therapies, Inc.
|
BEARISH | $6.39M | - | -320.5% | -% | $0.25 | Compare |
|
MGRX
Mangoceuticals, Inc.
|
BEARISH | $6.67M | - | -141.7% | -% | $0.39 | Compare |
|
QUCY
Mainz Biomed N.V.
|
BEARISH | $6.09M | - | -488.3% | -% | $0.49 | Compare |
|
BIAF
bioAffinity Technologies, Inc.
|
BEARISH | $6.07M | - | -245.2% | -217.5% | $1.35 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-24 | LEVY ADAM R | Chief Executive Officer | Sale | 10,000 | $15,947 |
| 2025-11-06 | LEVY ADAM R | Chief Executive Officer | Sale | 4,000 | $10,084 |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning NXGL from our newsroom.